An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature

Alopecia areata is a common autoimmune disease, with a negative impact in health‐related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)‐ or ANVISA (Agência N...

Descripción completa

Detalles Bibliográficos
Autores principales: Berbert Ferreira, Rachel, Ferreira, Sineida Berbert, Scheinberg, Morton Aaron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935663/
https://www.ncbi.nlm.nih.gov/pubmed/31893096
http://dx.doi.org/10.1002/ccr3.2484
_version_ 1783483613597138944
author Berbert Ferreira, Rachel
Ferreira, Sineida Berbert
Scheinberg, Morton Aaron
author_facet Berbert Ferreira, Rachel
Ferreira, Sineida Berbert
Scheinberg, Morton Aaron
author_sort Berbert Ferreira, Rachel
collection PubMed
description Alopecia areata is a common autoimmune disease, with a negative impact in health‐related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)‐ or ANVISA (Agência Nacional de Vigilância Sanitária)‐approved therapy for children with alopecia areata. JAK inhibitors are emerging as a promising therapy.
format Online
Article
Text
id pubmed-6935663
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-69356632019-12-31 An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature Berbert Ferreira, Rachel Ferreira, Sineida Berbert Scheinberg, Morton Aaron Clin Case Rep Case Reports Alopecia areata is a common autoimmune disease, with a negative impact in health‐related quality of life, especially when affecting children and adolescents. Current medical therapies, mainly for severe disease, are not effective. There are no FDA (Food and Drug Administration)‐ or ANVISA (Agência Nacional de Vigilância Sanitária)‐approved therapy for children with alopecia areata. JAK inhibitors are emerging as a promising therapy. John Wiley and Sons Inc. 2019-11-21 /pmc/articles/PMC6935663/ /pubmed/31893096 http://dx.doi.org/10.1002/ccr3.2484 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Berbert Ferreira, Rachel
Ferreira, Sineida Berbert
Scheinberg, Morton Aaron
An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
title An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
title_full An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
title_fullStr An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
title_full_unstemmed An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
title_short An excellent response to tofacitinib in a Brazilian adolescent patient with alopecia areata: A case report and a review of the literature
title_sort excellent response to tofacitinib in a brazilian adolescent patient with alopecia areata: a case report and a review of the literature
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935663/
https://www.ncbi.nlm.nih.gov/pubmed/31893096
http://dx.doi.org/10.1002/ccr3.2484
work_keys_str_mv AT berbertferreirarachel anexcellentresponsetotofacitinibinabrazilianadolescentpatientwithalopeciaareataacasereportandareviewoftheliterature
AT ferreirasineidaberbert anexcellentresponsetotofacitinibinabrazilianadolescentpatientwithalopeciaareataacasereportandareviewoftheliterature
AT scheinbergmortonaaron anexcellentresponsetotofacitinibinabrazilianadolescentpatientwithalopeciaareataacasereportandareviewoftheliterature
AT berbertferreirarachel excellentresponsetotofacitinibinabrazilianadolescentpatientwithalopeciaareataacasereportandareviewoftheliterature
AT ferreirasineidaberbert excellentresponsetotofacitinibinabrazilianadolescentpatientwithalopeciaareataacasereportandareviewoftheliterature
AT scheinbergmortonaaron excellentresponsetotofacitinibinabrazilianadolescentpatientwithalopeciaareataacasereportandareviewoftheliterature

Ejemplares similares